Weipeng Wang

Tumor Microenvironment & Drug Discovery Weipeng Wang, Ph.D. Professor No.199 Ren-ai Road , Dushu Lake Higher Education District College of Pharmaceutical Sciences, Soochow University Suzhou 215123, China. E-mail:wangweipeng@suda.edu.cn Tel/Fax: +86 512 6588 3761

RESEARCHS:

Dr. Wang’s lab is mainly focusing on the regulation of immune checkpoint molecules in gastrointestinal tumors, as well as their pro-tumorigenic roles in tumor microenvironment implicated in immune evasion, angiogenesis, ECM remodeling, metabolic reprogramming, chemoresistance, and metastasis, so as to discover novel anticancer targets and therapeutics.

MEMBERS:

(1) Vice President, Jiangsu Licensed Pharmacists Association

(2) Vice Chairman, The Youth Committee of Drug Metabolism of Chinese Pharmacological Society

(3) Associate Editor, Frontiers in Bioengineering and Biotechnology

(4) Director, Pharmaceutical Education Research Association, Medical Education Professional Committee, Chinese Higher Education Association

(5) Director, Medical Education Professional Committee, Jiangsu Higher Education Association

(6) Vice Chairman, Anti-infective Pharmacy Committee, Suzhou Pharmaceutical Association

FUNDINGS:

2023-2026: Research grant (PI), National Natural Science Foundation of China (#82273193)

2023-2025: Research grant (PI),Technology Research Project forNucleic Acid Drug, theNationalCenterofTechnology Innovation forBiopharmaceutical (NCTIB; #NCTIB2022HS02013)

2019-2022: Research grant (PI), Science and Technology Special Project of Clinical Medicine in Jiangsu Province (#BE2019657)

2018-2021: Research grant (PI), National Natural Science Foundation of China (#81773044)

2013-2016: Research grant (PI), National Natural Science Foundation of China (#81270031)

2012-2014: Research grant (PI), Natural Science Foundation of the Higher Education Institutions of Jiangsu Province (#12KJB320012)

2010-2012: Research grant (PI), National Natural Science Foundation of China (#30901360)

2010-2012: Research grant (Co-PI), National Natural Science Foundation of China (#30901361)

2009-2010: Research grant (PI), National Science Foundation for Post-doctoral Scientists of China (#20080441077)

2009-2010: Research grant (PI), National Science Foundation for Post-doctoral Scientists of Jiangsu province (#0802026C)

2009-2010: Research grant (PI), National Science Foundation for Young Teachers of Soochow University (#Q3132819)

2009-2011: Research grant (Co-PI), National Natural Science Foundation of China (#30800621)

AWARDS:

2020: Third Prize of Science and Technology Progress Award, Jiangsu Province

2019: Outstanding Young Teachers in Universities, Jiangsu Province

2018: The Second Prize of Scientific Research Outstanding Achievement Award (Science and Technology), the Ministry of Education, China

2018: Second Prize of Science and Technology Progress Award, Jiangsu Province

2017: First Prize of Chinese Medical Science and Technology Award for Popular Medical Sciences

2017: First Prize of Jiangsu Medical Science and Technology Award

2017: Second Prize of New Medical Technology Introduction Award, Jiangsu Province

2012: Young Scholar Award of Chinese Society of Immunology

PUBLICATIONS:

[1]Chen MX, Wang S, Zhang Q, Zhang YW, Wang MM, Guo XQ, Chen YS, Zhang HJ, Zhang HY*,Wang WP*. Facile Synthesis of Bifunctional Metal-Organic Frameworks Nanoparticles for Isolation of Extracellular Vesicles.ACS Sustain Chem Eng.2022 May 20; 10: 7020. (IF:9.2240/Q1)

[2]Lv YX, Zhang ZD, Tian S,Wang WP*, Li HQ*. Therapeutic potential of fucosyltransferases in cancer and recent development of targeted inhibitors.Drug Discov Today. 2022 Oct 9; 28(1):103394. (IF:8.369/Q1)

[3]Wang MM, Guo XQ, Yang M, Zhang YW, Meng FY, Chen YS, Chen MX, Qiu T, Li JW, Li Z, Zhang Q, Xu F, Zhang HY*,Wang WP*. Synergistic antitumor activity of 5-fluorouracil and atosiban against microsatellite stable colorectal cancer through restoring GATA3.Biochem Pharmacol.2022 Mar 30; 199: 115025. (IF:6.1004/Q1)

[4]Zhang YW, Wang MM, Meng FY, Yang M, Chen YS, Guo XQ, Wang WW, Zhu YF, Guo YD, Feng CL, Tian S, Zhang HJ, Li HQ*, Sun J*,Wang WP*. A novel SRSF3 inhibitor, SFI003, exerts anticancer activity against colorectal cancer by modulating the SRSF3/DHCR24/ROS axis.Cell Death Discov. 2022 May 2; 8(1):238. (IF:7.1089/Q2)

[5]Chen YS, Yang M, Meng FY, Zhang YW, Wang MM, Guo XQ, Yang J, Zhang HJ, Zhang HY*, Sun J*,Wang WP*. SRSF3 promotes angiogenesis in colorectal cancer by splicing SRF.Front Oncol.2022 Feb 7;12:810610. (IF:6.244/Q2)

[6]Zhang CX#, Chen YS#, Li FC#, Yang M, Meng FY, Zhang YW, Chen WC*,Wang WP*. B7-H3 is spliced by SRSF3 in colorectal cancer.Cancer Immunol Immunother.2021 Feb;70(2):311-321. (IF:6.968/Q2)

[7]Meng FY#, Yang M#, Chen YS#, Chen WC*,Wang WP*. miR-34a induces immunosuppression in colorectal carcinoma through modulating a SIRT1/NF-κB/B7-H3/TNF-α axis.Cancer Immunol Immunother.2021 Aug;70(8):2247-2259. (IF:6.968/Q2)

[8]Yang M#, Liu XC#, Meng FY, Zhang YW, Wang MM, Chen YS, Guo XQ, Chen WC*,Wang WP*. The rs7911488-T allele promotes the growth and metastasis of colorectal cancer through modulating miR-1307/PRRX1.Cell Death Dis.2020, 11(8): 651. (IF:9.6854/Q1)

[9]Yang JJ, Wang ZM, Liu S,Wang WP*, Zhang HJ, Gui CS*. Functional Characterization Reveals the Significance of Rare Coding Variations in Human Organic Anion Transporting Polypeptide 2B1 (SLCO2B1).Mol Pharm.2020 Oct 5;17(10):3966-3978. (IF:5.3640/Q2)